...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Cu (I) catalyzed alkyne-azide 1,3-dipolar cycloaddition (CuAAC): Synthesis of 17 alpha-[1-(substituted phenyl)-1,2,3-triazol-4-yl]-19-nortestosterone-17 beta-yl acetates targeting progestational and antipro-liferative activities
【24h】

Cu (I) catalyzed alkyne-azide 1,3-dipolar cycloaddition (CuAAC): Synthesis of 17 alpha-[1-(substituted phenyl)-1,2,3-triazol-4-yl]-19-nortestosterone-17 beta-yl acetates targeting progestational and antipro-liferative activities

机译:铜(I)催化炔叠氮化物1,3-偶极环加成(CuAAC):17α-[1-(取代的苯基)-1,2,3-三唑-4-基] -19-去甲睾酮17β的合成乙酸基乙酸酯靶向孕激素和抗增殖活性

获取原文
获取原文并翻译 | 示例

摘要

The progestational potency and selectivity of synthetic steroidal agonists can be enhanced by even larger chemical moieties at 17 alpha-position of the steroid backbones. Hereby a series 5a-c and 6a-c of novel 17 alpha-[1-substituted phenyl)-1,2,3-triazol-4-yl]-19-nortestosterone-17 beta-yl acetates were designed and synthesized using click chemistry approach searching progestogenic derivatives with potential anticancer activity. Compounds 5a,b and 6a,c have affected to different extents the three histopatho-logical parameters considered for evaluation of their progestational activity. The compounds 5a,b and 6a,c showed modifications in rat uterus at 35.7-34.8 nM levels with privileged endometrial thickening effect and least change of uterine weight relative to NEA at 52.9 nM level. Up to 40 mg/kg dose compounds 5b and 6c were non-toxic. Molecular docking of the ligands in PR showed in the majority of cases a conformational fitting into the active site different from that of the reference steroid NEA. Compound 6b revealed about 46.4% growth inhibition of CNS cancer SNB-75 cell line, 56% growth inhibition of renal cancer A498 cell line and 56.7% growth inhibition of prostate cancer PC-3 cell line which was mediated by cell cycle arrest. Drugability of the screened compounds showed tolerated results after being challenged to diverse physicochemical parameters. (C) 2015 Elsevier Masson SAS. All rights reserved.
机译:合成甾体激动剂的孕激素效力和选择性可以通过在甾体主链的17α-位处甚至更大的化学部分来增强。因此,设计并合成了一系列新颖的17α-[1-取代的苯基)-1,2,3-三唑-4-基] -19-去甲睾丸酮17β-乙酸基酯的5a-c和6a-c系列,化学方法搜索具有潜在抗癌活性的孕激素衍生物。化合物5a,5b和6a,6c在不同程度上影响了用于评估其孕激素活性的三个组织病理学参数。化合物5a,b和6a,c在大鼠子宫中显示出35.7-34.8nM水平的修饰,具有优先的子宫内膜增厚作用并且相对于NEA在52.9nM水平上子宫重量的变化最小。高达40 mg / kg剂量的化合物5b和6c无毒。在大多数情况下,PR中配体的分子对接显示出与参考类固醇NEA不同的构象适合于活性位点。化合物6b显示了CNS癌SNB-75细胞系的约46.4%的生长抑制,肾癌A498细胞系的约56%的生长抑制和前列腺癌PC-3细胞系的约56.7%的生长抑制,这是由细胞周期阻滞介导的。所筛选化合物的可药性在受到多种物理化学参数的挑战后显示出可耐受的结果。 (C)2015 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号